BNR Market Analysis
Overview
Price chart · mood · technical indicatorsFundamentals
Updated daily after market closeP/E ratio—
EPS (TTM)$-0.830.0% YoY
Profit margin-11.5%HEALTHCARE
Market cap$74.2MMicro cap
Valuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- 0.97
- P/S (TTM)
- 0.14
- EV/EBITDA
- -0.17
Profitability & growth
- ROE (TTM)
- -10.9%
- Operating margin
- -17.5%
- Revenue growth YoY
- -18.9%
- Dividend yield
- —
- Beta
- 1.32
Last earnings
Mar 31, 2026 · Reported $-0.21
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
News & Sentiment
50 articles · sorted by datePage 1 of 3 · 50 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
About Burning Rock Biotech Ltd
Company profileBurning Rock Biotech Limited primarily develops and provides screening tests for cancer therapies in the People's Republic of China. The company is headquartered in Guangzhou, China.
Classification
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Exchange
- NASDAQ
- Country
- China
- Currency
- USD
Company profile
- HQ
- NO. 5, XINGDAO RING ROAD NORTH, GUANGZHOU
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
Market cap$74.2M
Shares outstanding$8.8M
52W high$41.72
52W low$3.06
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent